ascidiathiazone A | 880137-41-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: ascidiathiazone A
• 英文别名: 2H-pyrido[2,3-g][1,4]benzothiazine-5,10-dione, 3,4-dihydro-1,1-dioxo-7-carboxylic acid；1,1,5,10-tetraoxo-3,4-dihydro-2H-pyrido[2,3-g][1,4]benzothiazine-7-carboxylic acid
• CAS: 880137-41-7
• 化学式: C₁₂H₈N₂O₆S
• 分子量: 308.271
• InChiKey: HNRNJVWZIQOLOL-UHFFFAOYSA-N

物化性质

• 熔点：
  155 °C (decomp)
• 沸点：
  698.2±55.0 °C(Predicted)
• 密度：
  1.83±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  139
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  ascidiathiazone A 在 氢氧化钾 、 氯化亚砜 作用下， 反应 4.5h， 生成 4H-pyrido[2,3-g][1,4]benzothiazine-5,10-dione-1,1-dioxo-7-carboxylic acid
  参考文献：
  名称：

  Anti-inflammatory Thiazine Alkaloids Isolated from the New Zealand Ascidian Aplidium sp.:  Inhibitors of the Neutrophil Respiratory Burst in a Model of Gouty Arthritis

  摘要：

  Ascidiathiazones A (3) and B (4), two new tricyclic thiazine-containing quinolinequinone alkaloids, were isolated from the New Zealand ascidian Aplidium species. Both compounds inhibited the in vitro production of superoxide by PMA-stimulated human neutrophils in a dose-dependent manner with IC50 1.55 +/- 0.32 and 0.44 +/- 0.09 mu M, respectively. In vivo inhibition of superoxide production by peritoneal neutrophils in a murine model of gout was observed for both compounds with oral doses of 25.6 mu mol/kg. Ascidiathiazone A (3) was synthesized in four steps from 8-hydroxyquinoline-2-carboxylic acid.

  DOI：

  10.1021/np060626o
• 作为产物：
  描述：

  methyl-2H-pyrido[2,3-g][1,4]benzothiazine-5,10-dione, 3,4-dihydro-1,1-dioxo-7-carboxylate 在 盐酸 作用下， 以 水 为溶剂， 反应 6.0h， 以68%的产率得到ascidiathiazone A
  参考文献：
  名称：

  [EN] ANTI-INFLAMMATORY COMPOUNDS
  [FR] COMPOSES ANTI-INFLAMMATOIRES

  摘要：

  本发明涉及式(I)或式(II)的化合物，具有抗炎活性，并包含一类新的非甾体抗炎药。因此，这些化合物可用于治疗炎症性疾病或疾患。本发明还涉及含有这些化合物的制药组合物，以及使用式(III)或式(IV)的化合物治疗炎症性疾病或疾患的方法。

  公开号：

  WO2006031134A1

文献信息

• Anti-Inflammatory Compounds
  申请人：Denny Alexander William

  公开号：US20070265253A1

  公开（公告）日：2007-11-15

  The invention relates to compounds of formula (I) or formula (II) which have anti-inflammatory activity and comprise a new class of NSAIDs. The compounds are therefore useful for treating inflammatory diseases or disorders. The invention also relates to pharmaceutical compositions containing these compounds, as well as methods of treating inflammatory diseases or disorders using compounds of formula (III) or formula (IV).

  本发明涉及具有抗炎活性的式（I）或式（II）化合物，包括一种新的非甾体抗炎药类。因此，这些化合物可用于治疗炎症性疾病或疾病。本发明还涉及含有这些化合物的制药组合物，以及使用式（III）或式（IV）化合物治疗炎症性疾病或疾病的方法。
• Synthesis and anti-inflammatory structure–activity relationships of thiazine–quinoline–quinones: Inhibitors of the neutrophil respiratory burst in a model of acute gouty arthritis
  作者：Elizabeth W. Chia、A. Norrie Pearce、Michael V. Berridge、Lesley Larsen、Nigel B. Perry、Catherine E. Sansom、Colette A. Godfrey、Lyall R. Hanton、Guo-Liang (Leon) Lu、Michaela Walton、William A. Denny、Victoria L. Webb、Brent R. Copp、Jacquie L. Harper

  DOI：10.1016/j.bmc.2008.09.052

  日期：2008.11

  Sixteen new thiazine-quinoline-quinones have been synthesised, plus one bicyclic analogue. These compounds inhibited neutrophil superoxide production in vitro with IC(50)s as low 60 nM. Compounds with high in vitro anti-inflammatory activity were also tested in a mouse model of acute inflammation. The most active compounds inhibited both neutrophil infiltration and superoxide production at doses 2.5 mu mol/kg, highlighting their potential for development as novel NSAIDs. (C) 2008 Elsevier Ltd. All rights reserved.
• US7807668B2
  申请人：——

  公开号：US7807668B2

  公开（公告）日：2010-10-05
• Anti-inflammatory Thiazine Alkaloids Isolated from the New Zealand Ascidian <i>Aplidium</i> sp.:  Inhibitors of the Neutrophil Respiratory Burst in a Model of Gouty Arthritis
  作者：A. Norrie Pearce、Elizabeth W. Chia、Michael V. Berridge、George R. Clark、Jacquie L. Harper、Lesley Larsen、Elizabeth W. Maas、Michael J. Page、Nigel B. Perry、Victoria L. Webb、Brent R. Copp

  DOI：10.1021/np060626o

  日期：2007.6.1

  Ascidiathiazones A (3) and B (4), two new tricyclic thiazine-containing quinolinequinone alkaloids, were isolated from the New Zealand ascidian Aplidium species. Both compounds inhibited the in vitro production of superoxide by PMA-stimulated human neutrophils in a dose-dependent manner with IC50 1.55 +/- 0.32 and 0.44 +/- 0.09 mu M, respectively. In vivo inhibition of superoxide production by peritoneal neutrophils in a murine model of gout was observed for both compounds with oral doses of 25.6 mu mol/kg. Ascidiathiazone A (3) was synthesized in four steps from 8-hydroxyquinoline-2-carboxylic acid.
• [EN] ANTI-INFLAMMATORY COMPOUNDS<br/>[FR] COMPOSES ANTI-INFLAMMATOIRES
  申请人：ITED NEW ZEALAND INST FOR CROP

  公开号：WO2006031134A1

  公开（公告）日：2006-03-23

  The invention relates to compounds of formula (I) or formula (II) which have anti-inflammatory activity and comprise a new class of NSAIDs. The compounds are therefore useful for treating inflammatory diseases or disorders. The invention also relates to pharmaceutical compositions containing these compounds, as well as methods of treating inflammatory diseases or disorders using compounds of formula (III) or formula (IV).

  本发明涉及式(I)或式(II)的化合物，具有抗炎活性，并包含一类新的非甾体抗炎药。因此，这些化合物可用于治疗炎症性疾病或疾患。本发明还涉及含有这些化合物的制药组合物，以及使用式(III)或式(IV)的化合物治疗炎症性疾病或疾患的方法。